Table 4.
Associations of CRH score with mortality in clinically meaningful subgroups of patients
| Multivariable analysis | |||
|---|---|---|---|
| Mortality under medical treatment | Mortality in patients with LVEF ≥ 50% | Mortality in patients with primary VHD | |
| Total cohort | |||
| Adjusted HR (95%CI) | 2.168 (1.946–2.416) | 2.072 (1.806–2.376) | 2.199 (1.876–2.578) |
| P value | < 0.001 | < 0.001 | < 0.001 |
| ASa | |||
| Adjusted HR (95%CI) | 2.499 (0.922–6.778) | 1.387 (0.776–2.481) | 1.791 (1.018–3.148) |
| P value | 0.072 | 0.270 | 0.043 |
| ARb | |||
| Adjusted HR (95%CI) | 4.435 (2.781–7.072) | 3.615 (2.110–6.193) | 3.289 (2.111–5.127) |
| P value | < 0.001 | < 0.001 | < 0.001 |
| MSc | |||
| Adjusted HR (95%CI) | 4.401 (1.155–16.778) | 10.749 (3.134–36.867) | 4.986 (2.069–12.016) |
| P value | 0.030 | < 0.001 | < 0.001 |
| MR | |||
| Adjusted HR (95%CI) | 1.994 (1.601–2.483) | 1.583 (1.112–2.253) | 2.242 (1.445–3.477) |
| P value | < 0.001 | 0.011 | < 0.001 |
| TR | |||
| Adjusted HR (95%CI) | 2.200 (1.758–2.751) | 2.581 (1.975–3.371) | 3.602 (2.158–6.013) |
| P value | < 0.001 | < 0.001 | < 0.001 |
| MVHD | |||
| Adjusted HR (95%CI) | 1.977 (1.642–2.380) | 1.857 (1.449–2.378) | 1.932 (1.485–2.514) |
| P value | < 0.001 | < 0.001 | < 0.001 |
Adjusted for age, sex, BMI, smoking status, hypertension, hyperlipidemia, diabetes, prior myocardial infarction, cardiomyopathy, atrial fibrillation or flutter, chronic lung disease, NYHA functional class, hemoglobin, LA, LVEDD, LVEF, pulmonary hypertension, severity of VHD, and valvular intervention
CRH cardio-renal-hepatic, LVEF left ventricular ejection fraction, VHD valvular heart disease, AS aortic stenosis, AR aortic regurgitation, MS mitral stenosis, MR mitral regurgitation, TR tricuspid regurgitation, MVHD multiple valvular heart disease, BMI body mass index, NYHA New York Heart Association, LA left atrial end-diastolic dimension, LVEDD left ventricular end-diastolic dimension, HR hazard ratio, CI confidence interval
aFor AS patients under medical treatment, cardiomyopathy was not adjusted because no death occurred in patients with cardiomyopathy. For AS patients with LVEF ≥ 50%, cardiomyopathy and CLD were not adjusted because no death occurred in patients with cardiomyopathy or CLD
bFor AR patients with LVEF ≥ 50%, cardiomyopathy was not adjusted because no death occurred in patients with cardiomyopathy
cAdjusted for age and sex